44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

Cancer relapse and mortality are problems, despite conventional chemo- and biotherapies. The modest efficacy of treatments for human cancers suggests that therapies do not eradicate all malignant ...